A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).
P. E. Goss
Honoraria - Pfizer
Research Funding - Pfizer
C. H. Barrios
Consultant or Advisory Role - Pfizer
A. Chan
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
S. K. L. Chia
Consultant or Advisory Role - Pfizer
S. Delaloge
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
B. Ejlertsen
Consultant or Advisory Role - Pfizer
J. N. Ingle
Consultant or Advisory Role - Pfizer
B. Moy
No relevant relationships to disclose
H. Iwata
No relevant relationships to disclose
F. A. Holmes
Consultant or Advisory Role - Philips Healthcare
Honoraria - Genentech; Novartis
J. Mansi
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
G. Von Minckwitz
Research Funding - Pfizer
L. Han
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
A. Thiele
Employment or Leadership Position - Pfizer
V. Agrapart
Employment or Leadership Position - Pfizer
A. Freyman
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
J. Truscello
Employment or Leadership Position - Pfizer
A. Berkenblit
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
D. Finkelstein
No relevant relationships to disclose